Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR3 | O14843 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.30 |
| ▸ | CETP | P11597 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19383627 | 0.98 | ALDH1A1 (0.38) | FFAR3ALDH1A1SMN1; SMN2TRPA1NPSR1 | |
| SCHEMBL3239419 | 0.98 | ALDH1A1 (0.38) | FFAR3ALDH1A1SMN1; SMN2TRPA1NPSR1 | |
| SCHEMBL16664136 | 0.91 | ALDH1A1 (0.35) | FFAR3ALDH1A1SMN1; SMN2HSD11B1CETP | |
| SCHEMBL1143457 | 0.90 | — | — | |
| SCHEMBL23124171 | 0.79 | FFAR3 (0.32) | FFAR3TRPA1 | |
| SCHEMBL7968390 | 0.77 | FFAR3 (0.38) | FFAR3ALDH1A1SMN1; SMN2HSD11B1CETP | |
| SCHEMBL9852700 | 0.77 | FFAR3 (0.38) | FFAR3ALDH1A1SMN1; SMN2HSD11B1CETP | |
| SCHEMBL7080167 | 0.75 | ALDH1A1 (0.39) | FFAR3ALDH1A1SMN1; SMN2TSHRHSD11B1 | |
| SCHEMBL22550126 | 0.75 | ALDH1A1 (0.39) | FFAR3ALDH1A1SMN1; SMN2TSHRHSD11B1 | |
| SCHEMBL12883183 | 0.75 | ALDH1A1 (0.39) | FFAR3ALDH1A1SMN1; SMN2TSHRHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7524837-B2 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA N.V. (BE) | 2009-04-28 | — | — | US | disclosed |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2007-04-12 | — | — | US | disclosed |
| WO-2006051312-A1 | GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-05-18 | — | — | WO | disclosed |
| US-20060003993-A1 | Benzotriazepnes as gastrin and cholecystokinin receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2006-01-05 | — | — | US | disclosed |
| EP-1443934-B1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2005-04-20 | — | — | EP | disclosed |
| US-20050026911-A1 | Benzotriazapinone salts and methods for using same | JANSSEN PHARMACEUTICA, N.V. (BE) | 2005-02-03 | — | — | US | disclosed |
| WO-2004101533-A1 | 1, 3, 4-BENZOTRIAZEPIN-2-ONE SALTS AND THEIR USE AS CCK RECEPTOR LIGANDS | JANSSEN PHARMACEUTICA, N.V. (US) | 2004-11-25 | — | — | WO | disclosed |
| WO-2004098610-A1 | BENZOTRIAZEPINE DERIVATIVES AND THEIR USE AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-11-18 | — | — | WO | disclosed |
| EP-1443934-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2004-08-11 | — | — | EP | disclosed |
| WO-2003041714-A1 | BENZOTRIAZEPINES AS GASTRIN AND CHOLECYSTOKININ RECEPTOR LIGANDS | JAMES BLACK FOUNDATION LIMITED (GB) | 2003-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050026911-A1 | Benzotriazapinone salts and methods for using same | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, SLC13A3, CLIC1 | FFAR3 1604/4885ALDH1A1 2875/4885SMN1; SMN2 3306/4885 |
| US-20070082892-A1 | Benzotriazepine derivatives and their use as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | FFAR3 326/4885ALDH1A1 2440/4885SMN1; SMN2 4457/4885 |
| US-20060003993-A1 | Benzotriazepnes as gastrin and cholecystokinin receptor ligands | CCKBR, GRPR, CCKAR | FFAR3 320/4885ALDH1A1 1894/4885SMN1; SMN2 4220/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.